Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	91
Drug interactions in people with HIV treated with antivirals for other viral illnesses	86
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress	63
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations	55
Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation	49
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	46
Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding	45
Review and evaluation of vancomycin dosing guidelines for obese individuals	38
Probing the mechanism of reduced in vivo potency of insulin detemir	35
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies	34
CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?	29
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	27
A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature	27
Drug-drug interactions between COVID-19 drug therapies and antidepressants	26
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	25
Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications	25
A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations	20
Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling	19
Induction effect of antiretroviral bictegravir on the expression of Abcb1, Abcg2 and Abcc1 genes associated with P-gp, BCRP and MRP1 transporters present in rat peripheral blood mononuclear cells	18
An update on microfluidic multi-organ-on-a-chip systems for reproducing drug pharmacokinetics: the current state-of-the-art	17
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	17
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects	16
The impact ofcatha edulis (vahl) forssk. ex endl. (celestraceae) (khat) on pharmacokinetics of clinically used drugs	16
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	16
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	16

Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis	15
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer	15
Comorbidities and the right dose: antipsychotics	15
Pharmacology of viable mechanism agnostic respiratory stimulants for the reversal of drug-induced respiratory depression in humans	15
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients	14
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice	13
Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials	13
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	13
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors	13
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment	12
Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development	12
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	12
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	12
Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations	12
Interactions between grapefruit juice and psychotropic medications: an update of the literature and an original case series	11
Guidance for interactions between antiseizure medications	11
Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine	11
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	11
Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future	11
Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics	10
Drug-drug interactions between antiseizure medications and antipsychotic medications: a narrative review and expert opinion	10
Drug-drug interactions between COVID-19 therapeutics and psychotropic medications	10
Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease	10
The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions	9
Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs	9
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	9
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis	9
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	9
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	9
Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil	9
Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants	9
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	9
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature	9
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	9
Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults	9
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia	8
Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections	8
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	8
The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV	8
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	8
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events	8
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	8
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	8
How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives	7
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	7
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics	7
The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients	7
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	7
Managing intoxications with nicotine-containing e-liquids	7
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence	7

Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug–drug interaction in healthy adults and its extrapolation to virtual chronic	6
Prescription of statins and pharmacokinetic interactions in Colombian patients	6
Ceftazidime dosing in obese patients: is it time for more?	6
A critical review of methotrexate clinical interactions: role of transporters	6
What is the significance of the impact of antipsychotics on the gut microbiome?	6
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	6
Pharmacogenetic guided drug therapy – how to deal with phenoconversion in polypharmacy	6
How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases?	6
Bioactivity descriptors for in vivo toxicity prediction: now and the future	6
Correction	5
A comprehensive review of the efficacy and safety of ertugliflozin	5
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	5
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s	5
The impact of pregnancy and associated hormones on the pharmacokinetics of Δ 9 -tetrahydrocannabinol	5
Advances in the understanding of acetaminophen toxicity mechanisms: a clinical toxicology perspective	5
Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models	5
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	5
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	5
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy	5
Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning	5
Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease	5
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	5
A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers	5
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	5
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	5
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	5
Evaluating the risk of toxicity and adverse drug interactions involving recreational GHB use and prescribed drugs	5
Risk factors associated with high-dose methotrexate induced toxicities	5
Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?	5
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	5
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more	5
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	5
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects	4
A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation	4
CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia	4
The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)	4
Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients	4
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	4
Therapeutic drug monitoring of TNFα inhibitors: a spotlight on novel techniques and assays	4
Personalization of drug dose thematic issue: introduction article	4
Examination of the emerging role of transporters in the assessment of nephrotoxicity	4
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	4
Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation	4
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke	4
Drug-drug interactions between psychotropic medications and oral contraceptives	4
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	4
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	4
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	4
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations	4
Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties	4
Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: in vitro and pharmacoepidemiological approaches	4
Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase	4
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	4
In silico prediction of drug-induced nephrotoxicity: current progress and pitfalls	4
Pharmacokinetics during therapeutic hypothermia in neonates: from pathophysiology to translational knowledge and physiologically-based pharmacokinetic (PBPK) modeling	3
The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients	3
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated	3
Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems	3
Renal and non-renal response of ABC and SLC transporters in chronic kidney disease	3
Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview	3
Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy	3
Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches	3
An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease	3
Biology and therapeutic applications of the proton-coupled folate transporter	3
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	3
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older	3
A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection	3
Deep learning neural network derivation and testing to distinguish acute poisonings	3
Drug-induced liver injury associated with the use of newer antiseizure medications in the elderly: an analysis of data from VigiBase	3
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	3
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics	3
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse	3
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	3
Exposure to antibiotics during pregnancy alters offspring outcomes	3
Genetic variation in organic cation transporters and considerations in drug development	2
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity	2
Drug–drug interactions in HIV-infected patients receiving chemotherapy	2
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	2
Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs	2
Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4	2

Pharmacogenomics in Asians: Differences and similarities with other human populations	2
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	2
An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables	2
Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook	2
New approach methods on the bench side to accelerate clinical trials during pregnancy	2
Drug–drug interactions involving antipsychotics and antihypertensives	2
JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations	2
Improving on in-silico prediction of oral drug bioavailability	2
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	2
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	2
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	2
Local anesthetics and erector spinae plane blocks: a spotlight on pharmacokinetic considerations and toxicity risks	2
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties	2
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	2
Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs	2
Investigative analysis of blood–brain barrier penetrating potential of electronic nicotine delivery systems (e-cigarettes) chemicals using predictive computational models	2
In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes	2
Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis	2
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	2
Recent advances in cell-based in vitro models for predicting drug permeability across brain, intestinal, and pulmonary barriers	2
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	2
Common gastrointestinal drug-drug interactions in geriatrics and the importance of careful planning	2
Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir	2
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	2
The influence of cardiopulmonary bypass on pediatric pharmacokinetics	2
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	2
A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar	2